May 13, 2021
Business News

GenScript Biotech BV and IES Diagnostics Forge Distribution Agreement for SARS-CoV-2 Neutralizing Antibody Kit


LEIDEN, Netherlands & BILBAO, Spain–()–GenScript Biotech (Netherlands) BV, a subsidiary of GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra.

The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2…



Click here to view the original article.

Related Posts

You might also like ...

Universal Display Corporation Announces Participation at Upcoming Conferences
Montrose Environmental Group to Attend Upcoming Investor Conferences
Pennsylvania American Water Signs Agreement to Purchase Foster Township West End Wastewater System